8 wyniki
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the US national stage of Application No. PCT/EP2007/061289, filed Oct. 22, 2007, which application claims priority from EP 06122820.1 filed Oct. 24, 2006.
The present invention is concerned with novel tetrahydro-naphthalene-1-carboxylic
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the US national stage of Application No. PCT/EP2007/061286, filed Oct. 22, 2007, which application claims priority from EP 06122817.7 filed Oct. 24, 2006.
The present invention is concerned with novel piperidine or piperazine substituted
TECHNICAL FIELD
The present invention relates to substituted sulfonamide compounds, to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and CNS disorders.
BACKGROUND
BACKGROUND OF THE INVENTION
This application is a divisional of application Ser. No. 10/131,987, filed on Apr. 25, 2002, now U.S. Pat. No. 6,525,075, filed on Feb. 25, 2003 which claims priority from provisional application Ser. No. 60/287,449, filed on Apr. 30, 2001, the entire disclosure of which
BACKGROUND OF THE INVENTION
Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%.
Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the
BACKGROUND OF THE INVENTION
Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%.
Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the
Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%.
Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the most prescribed drugs. They
BACKGROUND OF THE INVENTION
Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%.
Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the